|
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer Clinical research trials and Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer. Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer clinical trial. Human subjects often get the best healthcare possible for their Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer  Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
For Condition: stage 3A breast cancer,stage 3C breast cancer,stage 2 breast cancer,stage 3B breast cancer
Status: Recruiting
Sponsor(s): International Collaborative Cancer Group ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. Combining chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Randomizedphase III trial to compare the effectiveness of epirubicin and tamoxifen with or without docetaxel in treating postmenopausal women who have breast cancer that has spread to the lymph nodes.
Details: OBJECTIVES: - Compare the impact of adjuvant epirubicin with or without docetaxel and concurrent or sequential tamoxifen on time to relapse and overall survival in postmenopausal women with node-positive breast cancer. - Compare the toxic effects of these regimens in this patient population. - Compare the quality of life in terms of shift in long term toxicity and differences in recuperation in women treated with these regimens. - Compare the incidence of thromboembolic events during the first 9 months of study and the influence of such events on compliance in women treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to one of two adjuvant chemotherapy treatment arms within 30 days after surgery. - Arm I: Patients receive adjuvant epirubicin IV on days 1 and 8. Treatment continues every 28 days for 6 courses. - Arm II: Patients receive adjuvant epirubicin IV on days 1 and 8. Treatment continues every 28 days for 3 courses. Patients then receive docetaxel IV over 1 hour on day 1. Treatment continues every 21 days for 3 courses. Patients may be further randomized to one of two tamoxifen arms. Patients not randomized to the tamoxifen arms receive oral tamoxifen daily for 5 years concurrently with adjuvant chemotherapy. - Arm I: Patients receive tamoxifen as above concurrently with adjuvant chemotherapy. - Arm II: Patients receive sequential tamoxifen as above after completion of adjuvant chemotherapy. Quality of life is assessed at baseline, 9 months, 2 years, and then at 5 years. Patients are followed at 9 months, 1 year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven node-positive breast cancer - Postmenopausal - Last menstrual period more than 12 months before initial surgery OR - Any age with prior bilateral oophorectomy OR - Age 50 or over with prior hysterectomy without oophorectomy (unrelated to malignancy) - No distant metastases - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - See Disease Characteristics Sex: - Female Menopausal status: - See Disease Characteristics Performance status: - WHO (ECOG) 0-1 Life expectancy: - Not specified Hematopoietic: - WBC at least 3,000/mm3 OR - Absolute neutrophil count at least 1,500/mm3 - Platelet count at least 100,000/mm3 Hepatic: - Bilirubin normal - SGOT and SGPT no greater than 1.5 times normal - Alkaline phosphatase no greater than 1.5 times normal Renal: - Creatinine less than 1.5 times normal Cardiovascular: - No history of significant angina, congestive heart failure, or myocardial infarction within the past year - No clinically significant arrhythmias or uncontrolled hypertension - LVEF normal by MUGA, LV gated scan, or echocardiogram Other: - No other concurrent serious illness - No other prior or concurrent malignancy except adequately treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Not specified Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RaoulCoombes, Study Chair, Imperial College of Medicine
Charing Cross Hospital *Recruiting*
London, England, W12 0NN
United Kingdom
Recruiting Raoul Coombes 44-20-8383-5828
Additional Information:
Study ID Numbers: CDR0000068450; EU-20040,ICCG-C/14/96
Study Start Date:
Record last reviewed: February 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00010140
Other Stage 3b Breast Cancer Studies:
1. Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
2. Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
3. Erlotinib in Treating Women With Locally Advanced or Metastatic Breast Cancer
4. Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
5. Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
Related Studies:
Other stage 3B breast cancer Clinical Trials
Other England Clinical Trials
Other London Clinical Trials
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
|
|
|
|
|
|
|
|
